论文部分内容阅读
目的：探讨阿立哌唑治疗首发精神分裂症的临床疗效和安全性。方法将90例符合(CCMD-3)精神分裂症诊断标准的首发精神分裂症患者随机分为两组，每组各45例，分别给予阿立哌唑及利培酮治疗8w评定临床疗效。结果阿立哌唑有效率87.2%，显效率76.5%；利培酮有效率83.7%，显效率67.4%，两组治疗前与治疗后的PANSS评分相比差异无显著性(P>0.05)；阿立派唑不良反应少于利培酮。结论阿立哌唑治疗精神分裂症有较好的疗效，不良反应较培酮轻微，患者服药依从性良好。“,”Objective To study the clinical ef ects and safety of aripiprazole in the treatment of schizophrenia.Methods 90 patients with schizophrenia (CCMD-3) diagnostic criteria for schizophrenia were randomly divided into two groups, 45 cases in each group, were treated with aripiprazole and risperidone in the treatment of clinical ef icacy was assessed 8 weeks.Results The ef icacy rate of aripiprazole was 87.2%,in which 76.5% were improved markedly,The ef icacy rate of risperidone was 83.7%,in which 67.4% were improved markedly.The PANSS scores in both groups decreased significantly after treatment,aripiprazole has less side ef ects than risperidone.Conclusion Aripiprazole is of good ef icacy,high safety and less side ef ects in treating schizophrenia,and patients had bet er compliance.